Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Passes Above Two Hundred Day Moving Average of $0.32

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.32 and traded as high as $0.58. Brainstorm Cell Therapeutics shares last traded at $0.54, with a volume of 365,604 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a research report on Wednesday, March 27th. They set a “sell” rating on the stock.

Brainstorm Cell Therapeutics Price Performance

The business has a 50-day simple moving average of $0.47 and a two-hundred day simple moving average of $0.32. The stock has a market cap of $36.91 million, a price-to-earnings ratio of -1.32 and a beta of 0.27.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is owned by hedge funds and other institutional investors.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.